Company Description

Oryn Therapeutics is a clinical-stage company developing a new class of drug candidates, Orynotides. These proprietary drug candidates are uniquely engineered, stable, macrocyclic peptides with very low immunogenicity and favorable safety profile. They modulate pathologic inflammatory diseases and hold the ability to restore the immune homeostasis.